FDA Approves Bausch + Lomb's enVista Envy IOL for Full Range Vision Correction
• The FDA has approved Bausch + Lomb's enVista Envy IOL, offering a continuous range of vision and excellent dysphotopsia tolerance for cataract patients.
• Clinical trials showed 86% of patients reported minimal issues with dysphotopsia, such as glare and halos, after receiving the enVista Envy IOL.
• A Canadian study revealed that 94% of patients experienced little difficulty viewing close objects, with 93% satisfied with their vision post-surgery.
• The enVista Envy IOL will have limited U.S. availability in the coming weeks, with broader availability expected in 2025, and further regulatory approvals are being pursued.
© Copyright 2025. All Rights Reserved by MedPath